Filing Details

Accession Number:
0000950170-24-121727
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-11-05 19:14:25
Reporting Period:
2024-11-02
Accepted Time:
2024-11-05 19:14:25
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1357874 Precision Biosciences Inc DTIL Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1779581 Dario Scimeca C/O Precision Biosciences, Inc.
302 E Pettigrew Street, Suite A-100
Durham NC 27701
General Counsel And Secretary No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-11-02 1,836 $0.00 8,557 No 4 M Direct
Common Stock Disposition 2024-11-04 588 $8.19 7,969 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2024-11-02 1,836 $0.00 1,836 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1,835 No 4 M Direct
Footnotes
  1. Represents the vesting of Restricted Stock Units ("RSUs") on November 2, 2024.
  2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
  3. The sales were effected pursuant to a Rule 10b5-1 plan adopted on July 14, 2023. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.
  4. On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.